FDA Approves First-Ever Topical Gene Therapy for Dystrophic Epidermolysis Bullosa
The FDA has approved Vyjuvek (beremagene geperpavec-svdt), for the treatment of dystrophic epidermolysis bullosa (DEB).
The FDA has approved Vyjuvek (beremagene geperpavec-svdt), for the treatment of dystrophic epidermolysis bullosa (DEB).
Results from a phase 2 study of gusacitinib have demonstrated significant improvement in patients with chronic hand eczema.
The FDA has accepted the New Drug Application for investigational IDP-126 gel for the treatment of acne vulgaris.
Two phase 3 trials evaluated the use of Dupixent (dupilumab) in the treatment of prurigo nodularis in adults.
The FDA has approved Sculptra®, Galderma’s injectable poly-L-lactic acid to correct fine lines and wrinkles in the cheek area.
April W. Armstrong, MD, MPH appointed chief of the division of dermatology at University of California Health.
Tralokinumab clinical trial shows drug was well tolerated and efficacious in adolescents with moderate-to-severe atopic dermatitis (AD).
Researchers sought to understand patient perspectives relating to their experience, expectations, and preferences of psoriasis treatment.
The FDA has cleared Candesant Biomedical’s Brella™, a SweatControl Patch for the treatment of primary axillary hyperhidrosis in adults.
Arcutis Biotherapeutics has announced the FDA has accepted their NDA for roflumilast foam 0.3% for the treatment of seborrheic dermatitis.
A randomized phase 2 study evaluated the safety, efficacy, and tolerability of IDP-126 in pediatric patients with moderate-to-severe acne.
A group of 10 board-certified dermatologists conducted a Delphi consensus to evaluate the best methods for managing AMH.
The 2023 AAD Annual Meeting was buzzing with exciting news and breakthrough studies. Check out some of the latest clinical updates.
FDA to review supplemental Biologics License Application for Dupixent® (dupilumab) for chronic spontaneous urticaria (CSU).
The LiVDerm team caught up with Natasha A. Mesinkovska, MD, PhD at the 2023 SBS to chat about one of her areas of expertise, alopecia areata.
LiVDerm was honored to speak with Suneel Chilukuri, MD at the 2023 SBS Meeting where he shared his insights on the latest cosmetic devices.
Latanya T. Benjamin, MD has officially been named President-Elect of the Women’s Dermatologic Society.
A full recap of Day Two of the 2023 Masters of Pediatric Dermatology Symposium presented by leading industry experts.
Recent study examines how sarecycline works differently from broad-spectrum antibiotics and how this can be used for future treatments.
A full recap of the 2023 Masters of Pediatric Dermatology Symposium, the incredible two-day event which took place in Miami Beach.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
LiVDerm / South Beach Symposium
1801 N Military Trail, Ste 110
Boca Raton, FL, 33431
Copyright © 2025, LiVDerm. All Rights Reserved.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.